Ghost Tree Capital’s Aerie Pharmaceuticals AERI Stock Holding History

Ghost Tree Capital’s Portfolio AERI Stock Details AERI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-575,000	Closed	-$13.9M	–	63
2019 Q4	$13.9M	Buy	575,000 +350,000	+156%	+$7.25M	2.65%	10
2019 Q3	$4.33M	Buy	+225,000	New	+$5.15M	1.1%	29
2017 Q4	–	Sell	-75,000	Closed	-$3.65M	–	79
2017 Q3	$3.65M	Buy	+75,000	New	+$4.09M	0.77%	47
2017 Q1	–	Sell	-175,000	Closed	-$7.8M	–	87
2016 Q4	$6.62M	Buy	175,000 +50,000	+40%	+$1.89M	1.59%	25
2016 Q3	$4.72M	Buy	+125,000	New	+$2.76M	0.77%	45

Other funds holding AERI

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

LCS

Levin Capital Strategies New York $1.32B AUM 28.11% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Ghost Tree Capital's AERI Position: Q1 2020 in Review

Ghost Tree Capital sold out of Aerie Pharmaceuticals (AERI) in Q1 2020, closing a stake of 575,000 shares — an estimated $13.9M sold.

Ghost Tree Capital first reported a position in AERI in Q3 2016 and held it in 5 quarters. The position peaked at $13.9M in Q4 2019. 155 funds tracked by Wall St. Rank hold AERI as of Q1 2020.

Ghost Tree Capital reported no remaining Aerie Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
Ghost Tree Capital sold 575,000 Aerie Pharmaceuticals shares in Q1 2020, an estimated $13.9M.
Ghost Tree Capital first reported a position in Aerie Pharmaceuticals in Q3 2016 and held it in 5 quarters.
Ghost Tree Capital's Aerie Pharmaceuticals position peaked at $13.9M in Q4 2019.
155 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q1 2020.

Based on Ghost Tree Capital's 13F filing for Q1 2020, filed 15 May 2020.